Re: A Multicenter Randomized Phase II Trial of Lenvatinib plus Everolimus Versus Cabozantinib in Patients with Metastatic Clear Cell RCC that Progressed on PD-1 Immune Checkpoint Inhibition (LenCabo)

European Urology 2026

View at publisher

Authors: Wenhao Xu, Aihetaimujiang Anwaier, Siqi Zhou, Y. Zhu, Zhang Hu, Dingwei Ye

DOI: 10.1016/j.eururo.2025.11.020

Cited by: 0

References: 5

Fields of Study & Subjects

Renal cell carcinoma treatment Cancer Immunotherapy and Biomarkers Bladder and Urothelial Cancer Treatments

References 5